Summary Androgen administration can cause prostate cancer progression, and androgen deprivation therapy is a commonly used therapeutic modality in the treatment of prostate cancer. In trying to answer the posed clinical question, this article reviews the risks andD Landau...
Prostate cancer remains the most common non-skin malignancy in men in the United States, and as hypogonadism is being recognized and treated more, a dilemma has arisen: treating hypogonadism in men previously treated for prostate cancer. While testosterone replacement has traditionally been felt to ...
prostate cancerPSABACKGROUND. While the use of testosterone replacement therapy (TRT) in men undergoing active surveillance (AS) for prostate cancer (PCa) has been historically contraindicated, recent studies have contributed to a paradigm shift to this approach. AIM. To examine the impact of ...
The researchers found that prostate cancer cells are hardwired with a system that allows them to proliferate when the levels of testosterone are very low. But whenhormone levelsare elevated to resemble those present in the normal prostate, the cancer cells differentiate. "For decades, the goal of...
heighten the risk ofprostate cancerin humans," Bosland said. "While human studies are conducted, it would be prudent to limit testosterone prescriptions to men with symptomatic clinical hypogonadism and avoid testosterone use by men for non-medical purposes, including addressing normal signs of aging...
Although testosterone is often considered to be a catalyst of prostate cancer, a recent study suggests that the hormone may be able to subdue advanced prostate cancer and break down resistance to testosterone-blocking drugs used to treat the disease. ...
摘要: Testosterone therapy for men with prostate cancer is a controversial topic. A recent study retrospectively reviewed a single-centre experience in treating hypogonadal men with prostate cancer with exogenous testosterone therapy and found it to be safe....
We measured arterial stiffness (''compliance'') in 21 men receiving complete testosterone suppression therapy for prostate cancer, and in 25 controls. Systemic arterial compliance (SAC), which assesses proximal aortic stiffness, was calculated by simultaneous recording of aortic flow and carotid artery...
The use of testosterone therapy in men with prostate cancer was previously contraindicated, although recent data challenge this axiom. Over the past 2 decades, there has been a dramatic paradigm shift in beliefs, attitude, and treatment of testosterone deficiency in men with...
This phase IV trial studies the effects of testosterone replacement therapy (TRT) on treatment outcomes in hypogonadal men with prostate cancer that has not spread to other parts of the body (localized) and who are on active surveillance (AS). AS in prostate cancer involves closely watching the...